Intellia Therapeutics, Inc. (NTLA) Coverage Initiated by Analysts at Barclays PLC
Equities research analysts at Barclays PLC began coverage on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in a report released on Wednesday. The firm set an “overweight” rating on the stock.
Other analysts also recently issued reports about the company. Jefferies Group LLC reissued a “buy” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a report on Thursday, June 22nd. Credit Suisse Group set a $24.00 target price on Intellia Therapeutics and gave the company a “buy” rating in a report on Saturday, June 3rd. Chardan Capital reissued a “buy” rating and issued a $20.00 target price (up from $19.00) on shares of Intellia Therapeutics in a report on Wednesday, August 2nd. TheStreet raised Intellia Therapeutics from a “d+” rating to a “c-” rating in a report on Thursday, July 6th. Finally, Cann reissued a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $24.83.
Shares of Intellia Therapeutics (NASDAQ NTLA) traded down 2.21% on Wednesday, hitting $21.24. The stock had a trading volume of 286,616 shares. The stock has a 50 day moving average price of $17.28 and a 200-day moving average price of $14.95. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $22.49. The company’s market cap is $767.02 million.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The firm had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics’s quarterly revenue was up 40.5% on a year-over-year basis. On average, equities analysts expect that Intellia Therapeutics will post ($1.74) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Intellia Therapeutics, Inc. (NTLA) Coverage Initiated by Analysts at Barclays PLC” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/06/intellia-therapeutics-inc-ntla-coverage-initiated-by-analysts-at-barclays-plc.html.
In other Intellia Therapeutics news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total transaction of $2,436,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.80% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd purchased a new stake in Intellia Therapeutics during the 2nd quarter valued at approximately $167,000. California State Teachers Retirement System raised its stake in Intellia Therapeutics by 79.0% during the 2nd quarter. California State Teachers Retirement System now owns 25,143 shares of the company’s stock valued at $402,000 after acquiring an additional 11,100 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Intellia Therapeutics by 451.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,224 shares of the company’s stock valued at $212,000 after acquiring an additional 10,825 shares during the last quarter. State Street Corp raised its stake in Intellia Therapeutics by 52.0% during the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock valued at $2,638,000 after acquiring an additional 56,363 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Intellia Therapeutics by 19.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 48,566 shares of the company’s stock valued at $777,000 after acquiring an additional 7,866 shares during the last quarter. 46.52% of the stock is owned by hedge funds and other institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Stock Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related stocks with our FREE daily email newsletter.